Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al

Br J Haematol. 2015 Nov;171(4):665-8. doi: 10.1111/bjh.13430. Epub 2015 Apr 19.

Authors

Antonello Pinto¹, Gaetano Corazzelli²

Affiliations

¹ Haematology-Oncology and Stem Cell Transplantation Unit, Department of Haematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy. [email protected], [email protected].
² Haematology-Oncology and Stem Cell Transplantation Unit, Department of Haematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy.

PMID: 25892204
DOI: 10.1111/bjh.13430

No abstract available

Keywords: ABVD; Hodgkin lymphoma; dose intensity; doxorubicin; interim positron emission tomography.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / administration & dosage
Dacarbazine / administration & dosage
Doxorubicin / administration & dosage
Hodgkin Disease / drug therapy*
Humans
Vinblastine / administration & dosage

Substances

Bleomycin
Vinblastine
Dacarbazine
Doxorubicin

Supplementary concepts

ABVD protocol